An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.

International journal of molecular medicine

Volumn 13, Issue 2, 2004, Pages 249-255

  Emura, Tomohiro ^a   Nakagawa, Fumio ^a   Fujioka, Akio ^a   Ohshimo, Hideyuki ^a   Yokogawa, Tatsushi ^a   Okabe, Hiroyuki ^a   Kitazato, Kenji ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DNA; THYMIDINE PHOSPHORYLASE; TRIFLURIDINE;

ANIMAL; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IN VITRO STUDY; MOUSE; PANCREAS TUMOR; STOMACH TUMOR; TIME; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS; THYMIDINE PHOSPHORYLASE; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TRIFLURIDINE;

MLCS; MLOWN;

EID: 1442329642     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.13.2.249     Document Type: Article

References (0)